Synopsis
This guidance is being distributed for comment purposes only. Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at FDA: drugs ↗
